In 2005 the European Respiratory Society (ERS), in collaboration with The European Society for Clinical Microbiology and Infectious Diseases (ESCMID), published guidelines on the management of lower respiratory tract infections (LRTI) in adults [1]. This document was based on published scientific literature up to the end of 2002. We have now updated these guidelines to include publications to May 2010. The Taskforce responsible for guideline development has been sponsored by the ERS and ESCMID. Members of the Taskforce are members of the sponsoring ERS and/or ESCMID.
Our objective is to provide evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management of adult patients with LRTI. The target audience for the guidelines is thus all those whose routine practice includes the management of adult LRTI.
This document begins with definitions and background sections on microbial cause, resistance and pharmacokinetics/pharmacodynamics, with conventional referencing. The guideline section captures management outside hospital, management inside hospital (including community-acquired pneumonia (CAP), acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and acute exacerbations of bronchiectasis) and prevention. The guidelines are about the management of infection. This means that for conditions such as AECOPD, aspects of management that are unreleated to infection (e.g. use of steroids or bronchodilators) are not included. It contains the graded recommendations but also the background information for each recommendation, with details about each new cited reference and the evidence grades. Because this is an update, original data and publications have usually not been repeated and the reader is referred to the original publication for this. As this is an update using the same methodologies, the layout of the document, including text, recommendations and evidence tables, is the same as in 2005.
下呼吸道感染吃什么药 2011欧洲下呼吸道感染攻略
精彩推荐
- 口碑验证产品力,权益彰显诚意!问界新M5 Ultra销量稳居高位

在竞争日趋白热化的智能SUV市场,销量数据往往最能说明问题。问界新M5 Ultra用实实在在的市场表现证明了其过硬的产品力,自问界新M5 Ultra今年4月单月销量突破4000辆后,5...详细
- 口碑持续刷屏!问界新M5 Ultra以硬核实力成为年终品质之选

在竞争激烈的智能SUV市场,产品力的优劣永远是销量的终极试金石。问界新M5 Ultra的市场表现验证了这一准则。站在2025年的尾巴上,纵观这款车的市场表现,自2月以来,问界M5...详细
- 选车不纠结!特斯拉Model Y与问界新M5 Ultra全方位对比

在中型智能SUV市场,特斯拉Model Y凭借成熟的品牌口碑和市场积淀,一直是不少消费者的备选清单TOP1;而华为深度赋能的问界新M5 Ultra,凭借在智能科技与实用配置上的优势,...详细
- 问界新M5 Ultra与特斯拉Model Y,谁才是智慧出行伙伴?

金秋十月,正值传统购车旺季,汽车市场也迎来了一轮新品投放与促销热潮。对于众多持币待购的消费者而言,在竞争激烈的中型智能SUV市场中做出选择并非易事。其中,华为深度...详细
本周热门
- 同仁堂健康双十一活动开启 “象食养医”倡导从健康的时候就关注健康

如果你想了解自己身体的秘密,让健康成为日常的生活方式,保持年轻的状态,实现抗衰老,逆生长的美好愿望,那么今年双十一的这场活动你一定不要错过。11月1日,同仁堂健康...详细





